Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
19.76
-5.00 (-20.18%)
May 7, 2026, 12:35 PM EDT - Market open
Castle Biosciences Employees
Castle Biosciences had 883 employees as of December 31, 2025. The number of employees increased by 122 or 16.03% compared to the previous year.
Employees
883
Change
122
Growth
16.03%
Revenue / Employee
$384,960
Profits / Employee
-$14,532
Market Cap
598.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 883 | 122 | 16.03% | 883 | 0 |
| Sep 30, 2025 | 823 | 113 | 15.92% | 823 | 0 |
| Jun 30, 2025 | 798 | 95 | 13.51% | 798 | 0 |
| Mar 31, 2025 | 784 | 146 | 22.88% | 784 | 0 |
| Dec 31, 2024 | 761 | 151 | 24.75% | 761 | 0 |
| Sep 30, 2024 | 710 | 123 | 20.95% | 710 | 0 |
| Jun 30, 2024 | 703 | 121 | 20.79% | 703 | 0 |
| Mar 31, 2024 | 638 | 95 | 17.50% | 638 | 0 |
| Dec 31, 2023 | 610 | 67 | 12.34% | 610 | 0 |
| Sep 30, 2023 | 587 | 70 | 13.54% | 587 | 0 |
| Jun 30, 2023 | 582 | 100 | 20.75% | 582 | 0 |
| Dec 31, 2022 | 543 | 198 | 57.39% | 542 | 1 |
| Sep 30, 2022 | 517 | 206 | 66.24% | 517 | 0 |
| Jun 30, 2022 | 482 | 190 | 65.07% | 482 | 0 |
| Dec 31, 2021 | 345 | 144 | 71.64% | 342 | 3 |
| Sep 30, 2021 | 311 | 110 | 54.73% | 311 | 0 |
| Jun 30, 2021 | 292 | - | - | 292 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| GRAIL | 910 |
| CareDx | 765 |
| Burning Rock Biotech | 674 |
CSTL News
- 15 hours ago - Castle Biosciences reports Q1 EPS , consensus (49c) - TheFly
- 15 hours ago - Castle Biosciences raises 2026 revenue view to $345M-$355M from $340M-350M - TheFly
- 20 hours ago - Castle Biosciences Earnings Call Transcript: Q1 2026 - Transcripts
- 20 hours ago - Castle Biosciences Reports First Quarter 2026 Results - PRNewsWire
- 2 days ago - Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month - PRNewsWire
- 3 days ago - New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus - PRNewsWire
- 16 days ago - Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS - PRNewsWire
- 17 days ago - Castle Biosciences price target lowered to $40 from $50 at Canaccord - TheFly